An observational study in Uterine Fibroid, sponsored by InSightec. Recruiting at 6 sites in 2 countries. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-04-30.
Sponsored by InSightec · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Leiomyoma by InSightec — 1 open to participants now, 1 under way, none of them phase 3. Leiomyoma · InSightec.
Among the 10 studies in Leiomyoma by InSightec, this one is the only one that started in 2016, is the only observational one, and was the 10th registered.
438 studies on the registry are indexed under Leiomyoma; 74 are open to participants now.
Browse Leiomyoma studies →1 of the 10 studies in Leiomyoma by InSightec is open now, in 2 countries.
By country, each count listing its studies:
Of the 44 Leiomyoma studies recruiting now, 22 (50%) set no upper age limit and 21 (48%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2016.
This study's planned enrollment of 200 is above the median of 150 across 107 observational studies indexed under Leiomyoma.
Median enrollment 40 across the 9 interventional studies, 200 across the 1 observational. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
InSightec is the lead sponsor of 84 studies on the registry; 9 are open to participants now.
1 of the studies in Leiomyoma by InSightec that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05386615InSightecPost-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Leiomyoma by InSightec, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this Registry Study is to capture clinical pregnancy outcomes and fibroid treatment background data for any subject post-Exablate treatment for their symptomatic fibroids.
This is an observational study only for all consented subjects who undergo an Exablate treatment. The Exablate procedure is a commercial treatment. The objective of this registry is to collect data about the effect of Exablate treatment on potential pregnancy occurrences in this population for two years post-treatment for purposes of labeling updates and overall safety data collection.
pre- and peri- menopausal women with Uterine Fibroids
Inclusion Criteria: - - Eligibility is as per the symptomatic fibroids device indication. - All registry-consented patients following the treatment of their fibroid(s) with the Exablate system. Exclusion Criteria: -
Observational study of Exablate treatment.
Device: Body System - Functional
MR-Guided Focused Ultrasound
Occurrence of adverse events
All adverse events and/or serious adverse events will be documented and reported according to protocol.
Time frame: Through study completion, an average of 2 years.
Not enrolling at this site.
Started Feb 2016 (actual). Primary completion is estimated for Dec 2026, 130 months after the start.
Of 45 observational studies under Leiomyoma, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 99. This study's planned 130 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.